Kornimate/medical-research-clean huggingface dataset:
counseling intervention on severe nomophobia among health care providers

Conditions: Specific Phobia, Other

Summary: assess the effect of a counseling intervention adopted from heath belief model merged with multiple smart phone-based action cues on the level of nomophobia among participants with severe nomophobia assess the effect of a counseling intervention adopted from heath belief model merged with multiple smart phone-based action cues on the level of nomophobia among participants with severe nomophobia

in this study we seek to find if there is a relation between nomophobia level, self-esteem and mental health status, and discover whether a counseling intervention based on health belief model merged with smart phone-based action cues will decrease the level of nomophobia in participants with severe nomophobia. through an intervention based on health belief model merged with multiple smart phone action cues employed on the intervention group during 3 counselling sessions

Eligibility criteria:
inclusion criteria: * owning and actively using a smartphone. * understanding verbal english instructions. * willing to participate in a possible counseling session * physicians currently working in kasr alainy hospital exclusion criteria: * having any diagnosed psychiatric disorder. * participants taking medications that could affect psychological status e.g: b blockers, mood stabilizers.

Keywords: nomophobia health care providers self-esteem mental health
endovascular function in atrial fibrillation (af) patients

Conditions: PAT Result

Summary: 1. recruit 50 patients with atrial fibrillation and 30 controls 2. endovascular function assessment with peripheral arterial tonometry (pat) 3. follow up the occurence of af


Eligibility criteria:
inclusion criteria: * ≥2 paroxysmal (electrocardiographic documentation of at least 1) af episodes lasting ≥1 hour in duration: (that terminate spontaneously within 7 days or cardioversion is performed within 48h of af onset): or * electrocardiographic documentation of 1 persistent af episode: (sustained for ≥7 days or cardioversion is performed more than 48h after af onset): or * electrocardiographic documentation of 1 longstanding persistent af episode: (continuous af of duration \>1 year). exclusion criteria: * patients with cerebralvascular disease * patients with coronary disease * patients with peripheric artery disease
topical paromomycin for cutaneous leishmaniasis in bolivia

Conditions: Leishmaniasis, Cutaneous; Leishmania Braziliensis Complex; Leishmaniasis, American; Leishmaniasis; American, Cutaneous

Summary: this protocol will compare topical paromomycin to standard intralesional (il) antimony (sb) to placebo for l braziliensis in bolivia.

patients will be randomized between paromomycin cream applied topically once daily for 20 days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days 1, 3, 5 (group 2-20 patients), and cream vehicle applied topically once daily for 20 days (group 3-20 patients). after treatment, all patients will be followed for 1, 3, and 6 months.

Eligibility criteria:
inclusion criteria: * gender: male or female * age: \>12 yrs of age * presentation: 1-to-2 ulcerative lesions, each \< 30 mm in largest diameter and with a total lesion area \<900 mm2. * parasitology: parasitological confirmation of the lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion. exclusion criteria: * previous treatment for leishmaniasis with sb, pentamidine, amphotericin b, miltefosine, imidazoles, allopurinol in the last 3 months. * other diseases that would be likely in the pi's opinion to interact, either positively or negatively, with treatment.

Keywords: leishmaniasis l.braziliensis paromomycin cream intralesional pentamidine leishmaniasis local therapy
predicting outcome of cytoreduction in advanced ovarian cancer

Conditions: Ovarian Cancer Stage III; Ovarian Cancer Stage IV

Summary: predatoor is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using camera vision (cv) to predict outcomes of cyto reduction at the time of diagnostic laparoscopy.

for the treatment of advanced ovarian cancer, the decision to undergo primary surgery is complex and decided by the surgeon while multiple considering multiple elements. sometimes, chemotherapy is needed before surgery to shrink some of the tumours. to choose the best patients for primary surgery, several prediction tools have been developed. ct and mri have most commonly been used to identify sites and amounts of tumors in the abdomen and can help determine if these tumours can be safely removed by surgery. however, these imaging methods are only a prediction, and sometimes a diagnostic laparoscopy (putting a camera in the abdomen to look at all sites of disease) is performed to help this decision process. with the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. in particular, the investigators would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumours can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. the investigators will enroll patients at a one-time point (being the time of surgery) and follow them forward in time and there will be no additional visits other than the surgery. during surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. these images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.

Eligibility criteria:
inclusion criteria: * patients treated at fondazione policlinico gemelli hospital, rome italy, trillium -credit valley hospital, mississauga, ontario and princess margaret cancer centre, toronto, canada * patients fit for cytoreductive surgery * patients with a primary diagnosis of suspect stage iii-iv ovarian cancer * patients selected for interval cytoreductive surgery after nact exclusion criteria: * patients with pre-operative stage i-ii disease confined to the pelvis * patients unfit for surgery * lack of information about patients' surgical outcomes and clinicopathological characteristics * lgsoc, clear cell and mucinous, non-epithelial histologic subtypes (if available)
length of stay in nvaf patients hospitalized and initiated with dabigatran or warfarin in japan

Conditions: Atrial Fibrillation

Summary: the primary objective of this study is to compare the length of stay from treatment of oral anticoagulant initiation to hospital discharge of patients hospitalized and subsequently treated with dabigatran or warfarin for non-valvular atrial fibrillation in a real-world japanese clinical practice. the secondary objective of the study is to compare los of patients hospitalized with 1) acute ischemic stroke, and 2) due to non-valvular atrial fibrillation. other objectives are (1) to compare the in-hospital direct and indirect-related costs between dabigatran and warfarin, and (2) to compare the rates of patients directly discharged at home after the index hospitalization between dabigatran and warfarin.


Eligibility criteria:
inclusion criteria: 1. hospitalized patients among patients having a visit record with a confirmed diagnosis of nvaf (icd-10 code: i48) and prescribed dabigatran or warfarin in the hospitalization period exclusion criteria: 1. having a record with a diagnosis of atrial flutter, valvular atrial fibrillation or postoperative atrial fibrillation diagnosis as standard disease name during the study period. 2. having a record with a diagnosis of rheumatic atrial fibrillation (icd-10 code i05 to i09 \[chronic rheumatic atrial fibrillation\])or mechanical-valvular atrial fibrillation (icd-10 code t820 \[artificial cardiac valve mechanical complication\]) during the study period. 3. having a record with a confirmed diagnosis of cancer (icd-10 code c00-c97 \[malignant neoplasm\]) during the study period. 4. having a record of dialysis (class j038 artificial kidney) during the study period. 5. having a record of dabigatran use for a purpose other than prevention of ischemic stroke and systemic embolism in non-valvular atrial fibrillation patients. 6. having a record of dabigatran or warfarin before the hospitalization 7. having a record of new diagnosis of atrial fibrillation after the initiation of dabigatran or warfarin treatment in the hospitalization period.
safety and efficacy study of np001 in patients with amyotrophic lateral sclerosis (als) and systemic inflammation

Conditions: Amyotrophic Lateral Sclerosis

Summary: this study evaluates np001 in patients with amyotrophic lateral sclerosis (als) and evidence of systemic inflammation. half of participants will receive np001 and the other half will receive placebo.

this is a randomized, double-blind, placebo-controlled study of np001 in subjects with als and evidence of elevated systemic inflammation. subjects will be allocated (1:1) to np001 and placebo. drug or placebo will be given intravenously.

Eligibility criteria:
key inclusion criteria: * diagnosis of clinically possible, clinically probable (with or without laboratory support), or clinically definite als (using the revised el escorial criteria) * forced vital capacity greater than or equal to 65% of that predicted for age and height * onset of als-related weakness less than 3 years prior to first dose of study drug * plasma high sensitivity c-reactive protein (hs-crp) concentration of greater than or equal to 0.113 mg/dl at pre-screening/screening * stable dose (greater than 30 days) of riluzole if undergoing treatment with this agent * for females: not be of childbearing potential or agree to use adequate birth control during the study key exclusion criteria: * life expectancy of less than 6 months * tracheotomy or be using ventilatory assistance, including bi-level positive airway pressure (bipap) or continuous positive airway pressure (cpap) * active pulmonary disease * gastrostomy * stem cell therapy * immune modulator therapy or participation in studies of other agents within 12 weeks of pre-screening/screening * unstable medical condition other than als

Keywords: als amyotrophic lateral sclerosis motor neuron disease central nervous system diseases nervous system diseases neurodegenerative diseases neuromuscular diseases inflammation c-reactive protein
sex-specific effects of endocrine disruption on aging and alzheimer's disease

Conditions: Alzheimer Disease

Summary: the researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing alzheimer's disease in women.

the proposed project will enroll 200 women. each women will have one clinic visit consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. all women will also undergo clinical neuroimaging, which includes structural mri, β-amyloid (aβ) deposition on pet as a biomarker of aβ pathology, and tau deposition on pet as a marker of neurofibrillary tangles using av-1451.

Eligibility criteria:
inclusion criteria: * women who lived in olmsted county, minnesota between 1988 and 2007 * currently aged 55 years and older * more than six months post chemotherapy or major surgery requiring general anesthesia * willing and able to sign informed consent exclusion criteria: * not able to read and speak english * in hospice * claustrophobic * if undergoing tau imaging, cannot have qt prolongation
study of chemotherapy combination with autologous cytokine-induced killer cell immunotherapy to treat lung cancer

Conditions: Non-small Cell Lung Cancer; Squamous Cell Carcinoma

Summary: this randomized, multicenter,open-label phase ii/iii study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer cell immunotherapy in patients with stage iiib-iv squamous non-small-cell lung cancer

1. phase ii/iii study, 2. randomized, multicenter, open-label study, 3. evaluated the effects of chemotherapy combination with autologous cytokine-induced killer cell immunotherapy compared with chemotherapy in patients with stage iiib-iv squamous non-small-cell lung cancer

Eligibility criteria:
inclusion criteria: * sex: male or female * age: from 18 to 80 years * histology: squamous non-small-cell lung cancer * clinical stage: from stage iiib to stage iv * therapy: not received chemotherapy, radiotherapy, or immunotherapy before entry into this study * karnofsky performance status: more than 50% * expected survival: more than 2 months * laboratory tests results 7 days before the start of treatment: white blood cells: more than 3.0 × 109/l platelets: more than 100 × 109/l neutrophils: more than 1.5 × 109/l hemoglobin: more than 80g/l serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (uln) serum glutamic-oxal (o) acetic transaminase: less than 2.5 × uln serum bilirubin: less than 1.25 × uln serum creatinine: less than 1.25 × uln * pregnancy test: the test of women of child-bearing period must be negative 7 days before the start of treatment * contraception: male and female subjects of child-bearing period must adopt a reliable method of contraception before entry into this study until 30 days after stopping this study * informed consent: subject must have the ability to understand and voluntarily sign a written informed consent exclusion criteria: * history of neoplasms: other neoplasms * medical history: mental disease, or congestive heart failure, or severe coronary artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy * history of allergies: allergic to the study drugs * metastasis: clinical symptoms of brain metastasis * other clinical trial: the subject received other clinical trial before this study * laboratory tests: the serum test of human immunodeficiency virus, or hepatitis b virus, or hepatitis c virus was positive * woman: pregnant or lactating women * compliance: poor compliance * history of neoplasms: other neoplasms
effect of 980nm diode laser on postoperative pain and root canal disinfection in endodontic retreatment cases

Conditions: Postoperative Pain

Summary: a randomized clinical trial that evaluates the effect of using 980nm diode laser intracanal irradiation on postoperative pain and root canal disinfection in endodontic retreatment cases with chronic periapical lesions

the endodontic retreatment procedures will be carried out for the participants, then 980nm diode laser will be used to disinfect root canals. the researcher will then take microbiological samples of the root canals, to determine count and type of microorganisms in root canals. the subject will be asked to determine his level of pain at 7 days after endodontic retreatment procedures in a visual analogue scale (vas), and to determine number of analgesic tablets needed to relieve his pain in the given charts. the subject will then return to the clinic 7 days later to bring back his charts. the researcher then will take another microbiological sample of the root canals, and complete the endodontic retreatment procedures.

Eligibility criteria:
inclusion criteria: 1. endodontic retreatment cases of single rooted teeth with chronic periapical lesions; with periapical radiolucency of less than 1 cm diameter will be selected. 2. teeth with straight root canals. 3. subjects aged between 18-50 years of age. 4. no contributory medical history. 5. no previous administration of analgesics and / or antibiotics within the previous 2 weeks. exclusion criteria: 1. retreatment cases with complications such as separated instruments, perforations, ledges, resorption, transportation, calcifications, immature apices and over fillings. 2. teeth with curved roots. 3. swelling or sinus tract. 4. mutilated teeth that interfere with proper isolation and seal between visits. 5. subjects with generalized periodontitis, or if the tooth has probing depth of more than 3 mm. 6. subjects with uncontrolled diabetes or debilitating diseases. 7. pregnant or nursing females. 8. systemic disorders that necessitate antibiotic prophylaxis or prevent the use of ibuprofen.
study of memantine to treat huntington's disease

Conditions: Huntington's Disease

Summary: to determine if memantine in doses of 10 mg bid affects memory, cognition, and behavior in patients with huntington's disease (hd).

results of several published clinical trials suggest that memantine has a beneficial effect in dementing conditions, such as alzheimer's disease; however, the effects of memantine on cognitive and behavioral function in hd are unknown. our hypotheses are that hd patients who are administered memantine will show improved performance on psychometric tests of memory and executive functions in addition to behavior and that patients treated with memantine will show more improvement after six months than after three months of treatment.

Eligibility criteria:
inclusion criteria: * men or women aged 18 or older. * diagnosis of hd with current complaints of memory or concentration difficulties. * dementia rating scale score of \<129, to ensure that patients have sufficient cognitive impairment. * adequate visual and auditory acuity to allow neuropsychological testing. * good general health with no additional diseases expected to interfere with the study. * patient is not institutionalized. * sufficient english skills to complete all testing without assistance of an english language interpreter. * availability of a responsible caregiver who agrees to supervise administration of study drug, monitor the patient's compliance and adverse events, and accompany the patient to all clinic visits. exclusion criteria: * 1. any significant neurologic disease other than hd. * severe psychotic features or other severe psychiatric problems within the last three months which could lead to difficulty complying with the protocol. * history of alcohol or substance abuse within the past two years (dsm iv criteria). * any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol. * history of mi in the past year or head trauma with loss of consciousness greater than 20 minutes. * insulin-requiring diabetes. * use of any fda approved cognitive enhancing prescription medications or investigational drugs within 30 days. * use of ginkgo biloba or dhea within four weeks prior to baseline. * use of narcotic analgesics within 4 weeks prior to baseline. * patients who, in the investigator's opinion, would not comply with study procedures.
assessment of subject use of the rebiject ii injection device according to nurse examination of subject accuracy in 10 steps as a dummy demonstration

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is a chronic, inflammatory, demyelinating disease of the central nervous system (cns) and is one of the most common causes of neurological disability in young adults. rebif is licensed in the united kingdom for the treatment of relapsing ms and is given 3 times per week by subcutaneous injection. the rebiject ii device is an autoinjector which allows patients easier administration of their rebif injections. prior to treatment, patients receive training on the use of the device and its maintenance. currently, all treatments for ms are injectable and require long term patient commitment. rebiject has been developed to improve patient convenience and comfort but does require multiple steps to be carried out in order for the injection to be delivered correctly. reports from our local call centre and nurse advisors suggest that inaccuracies of use with the rebiject device are common. by raising awareness of the level of inaccuracy and determining which steps patients are most likely not to complete correctly, modified training programs or modifications to current subject training may be put into place to address these issues. it is also important to demonstrate the link between poor use of the medication device and increased relapse rates or increased injection site reactions.


Eligibility criteria:
inclusion criteria: * have relapsing remitting multiple sclerosis and currently receiving rebif treatment and using the rebiject ii injection device * be under regular review by a ms nurse * be aged 18 or above * be willing and able to participate in the trial and to have provided written informed consent exclusion criteria: * receiving disease modifying therapy other than rebif * receiving rebif but not using the rebiject ii injection device * do not self inject * are unable or unwilling to provide informed consent

Keywords: multiple sclerosis rebif interferon beta-1a
measurement of adherence to art in hiv-infected children in uganda (the charta study)

Conditions: HIV; HIV Infections

Summary: this study will compare methods of determining whether hiv-infected children take their medications.

hiv is a virus that weakens people's immune systems and can cause aids. antiretroviral therapy (art) is a treatment for hiv that combines different types of antiretroviral medications, but it must be taken throughout a person's life without missing doses to be effective. when people do miss doses, the hiv virus has an opportunity to develop resistance to the medications, making them less effective in the future. reports indicate that as many as 50% of children infected with hiv who are living in resource-limited countries regularly miss doses of their art. this study will test different methods for determining children's rates of adherence to art medications. this will both define the exact magnitude of the problem and direct future efforts in increasing art adherence in children. participation in this study will last 12 months. all children enrolled will undergo a series of assessments of medication adherence. at baseline and every month over the course of the study, researchers will make unannounced home visits to measure the amount of medicine that remains untaken by participants and to record how many times the electronic cap on participants' medication bottles have been removed. participants with cell phones will also receive monthly phone calls during which they will be asked to measure the amount of their medicine that remains untaken. at study entry and after 6 and 12 months, researchers will also examine child participants' medical records and the results of their regularly scheduled blood tests. at these blood tests, an additional half teaspoon of blood, which may be used in future testing, will be collected and stored by the researchers. after 3, 6, 9, and 12 months, researchers will request to collect hair samples from child participants to test levels of hiv medications in the hair, but participation in this part of the study is optional. assessments of reasons for medication adherence will also be performed. at study entry and after 3, 6, 9, and 12 months, children and their parents will complete questionnaires about their understanding of hiv medicines and hiv infection, motivation for the child to take medications, behaviors related to taking medications, and basic personal information. one and 7 months after study entry, some parent participants will also complete interviews with study staff about giving hiv medicines to their children.

Eligibility criteria:
inclusion criteria: * hiv-infected * receiving highly active antiretroviral therapy (haart) through the children's hiv/aids care clinic * resident in the mbarara district, defined as living within 30 km or a 2-hour driving radius of the city of mbarara * plans to stay within the mbarara district for the next year exclusion criteria: * attendance at a boarding school

Keywords: aids adherence to antiretroviral therapy pediatric resource limited setting treatment experienced